Creating new drugs that help destroy specific proteins in cells
Development of Ubiquitin-Independent Degraders
['FUNDING_R01'] · UNIVERSITY OF FLORIDA · NIH-10914808
This study is exploring new ways to create special compounds that can help your body get rid of harmful proteins that can cause health problems, making it easier to keep your cells healthy and potentially leading to better treatments for diseases linked to these proteins.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-10914808 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative chemical compounds known as degraders that can effectively target and eliminate specific proteins within cells. By recruiting these proteins directly to the proteasome, the research aims to simplify the process of protein destruction, which is crucial for maintaining cellular health. The approach involves enhancing protein-protein interactions to ensure that the targeted proteins are efficiently degraded without the need for prior modification. This could lead to more effective treatments for diseases caused by dysfunctional proteins.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals with conditions linked to protein misfolding or accumulation, such as certain cancers or neurodegenerative diseases.
Not a fit: Patients with conditions not related to protein degradation or those whose diseases do not involve the targeted proteins may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively eliminate harmful proteins associated with various diseases.
How similar studies have performed: Other research has shown promise in developing similar degraders, indicating a potential for success in this novel approach.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KODADEK, THOMAS J. — UNIVERSITY OF FLORIDA
- Study coordinator: KODADEK, THOMAS J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.